Author:
Ma Yipeng,Liu Fenglan,Li Bin,Peng Kaiqi,Zhou Hong,Xu You,Qiao Dongjuan,Deng Lijuan,Tian Geng,Nielsen Morten,Wang Mingjun
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference41 articles.
1. D.V. Parums, Editorial: current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients, Med. Sci. Monit. 28 (2022) e935952.
2. A. Jayk Bernal, M.M. Gomes da Silva, D.B. Musungaie, E. Kovalchuk, A. Gonzalez, V. Delos Reyes, A. Martin-Quiros, Y. Caraco, A. Williams-Diaz, M.L. Brown, J. Du, A. Pedley, C. Assaid, J. Strizki, J.A. Grobler, H.H. Shamsuddin, R. Tipping, H. Wan, A. Paschke, J.R. Butterton, M.G. Johnson, C. De Anda, M.O.-O.S. Group, Molnupiravir for oral treatment of covid-19 in nonhospitalized patients, N. Engl. J. Med. (2021).
3. Mosaic structure of human coronavirus NL63, one thousand years of evolution;Pyrc;J. Mol. Biol.,2006
4. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift;Cameroni;Nature,2022
5. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic;Hoffmann;Cell,2021